Medacta Group SA

BATS-CHIXE:MOVEZ Stock Report

Market Cap: CHF 2.1b

Medacta Group Valuation

Is MOVEZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MOVEZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MOVEZ (CHF106.2) is trading above our estimate of fair value (CHF74.78)

Significantly Below Fair Value: MOVEZ is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MOVEZ?

Key metric: As MOVEZ is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for MOVEZ. This is calculated by dividing MOVEZ's market cap by their current earnings.
What is MOVEZ's PE Ratio?
PE Ratio40.5x
Earnings€56.21m
Market Cap€2.28b

Price to Earnings Ratio vs Peers

How does MOVEZ's PE Ratio compare to its peers?

The above table shows the PE ratio for MOVEZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average30.1x
SN. Smith & Nephew
35x22.7%UK£8.5b
NIOX NIOX Group
22.9x15.8%UK£251.5m
EKF EKF Diagnostics Holdings
25.3xn/aUK£120.7m
CTEC ConvaTec Group
37.1x20.2%UK£4.5b
MOVEZ Medacta Group
40.5x21.1%CHF 2.1b

Price-To-Earnings vs Peers: MOVEZ is expensive based on its Price-To-Earnings Ratio (40.5x) compared to the peer average (30.1x).

Price to Earnings Ratio vs Industry

How does MOVEZ's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No. of Companies9PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: MOVEZ is expensive based on its Price-To-Earnings Ratio (40.5x) compared to the European Medical Equipment industry average (29.6x).

Price to Earnings Ratio vs Fair Ratio

What is MOVEZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MOVEZ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio40.5x
Fair PE Ratio33.5x

Price-To-Earnings vs Fair Ratio: MOVEZ is expensive based on its Price-To-Earnings Ratio (40.5x) compared to the estimated Fair Price-To-Earnings Ratio (33.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MOVEZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 106.20
CHF 139.84
+31.7%
3.5%CHF 148.57CHF 134.15n/a5
Dec ’25CHF 110.00
CHF 139.84
+27.1%
3.5%CHF 148.57CHF 134.15n/a5
Nov ’25CHF 114.60
CHF 139.63
+21.8%
4.2%CHF 149.11CHF 131.07n/a5
Oct ’25CHF 123.20
CHF 138.53
+12.4%
3.9%CHF 147.93CHF 132.44n/a7
Sep ’25CHF 130.70
CHF 140.13
+7.2%
3.8%CHF 150.12CHF 134.40n/a7
Aug ’25CHF 125.60
CHF 140.13
+11.6%
3.8%CHF 150.12CHF 134.40n/a7
Jul ’25CHF 122.60
CHF 139.19
+13.5%
4.2%CHF 148.77CHF 129.61n/a7
Jun ’25CHF 123.10
CHF 143.01
+16.2%
5.6%CHF 155.92CHF 131.46n/a7
May ’25CHF 111.80
CHF 143.01
+27.9%
5.6%CHF 155.92CHF 131.46n/a7
Apr ’25CHF 121.80
CHF 142.18
+16.7%
5.4%CHF 154.22CHF 130.04n/a7
Mar ’25CHF 127.80
CHF 140.59
+10.0%
7.3%CHF 156.49CHF 126.46n/a7
Feb ’25CHF 130.70
CHF 138.68
+6.1%
7.0%CHF 152.47CHF 125.02n/a7
Jan ’25CHF 126.00
CHF 133.43
+5.9%
10.8%CHF 152.89CHF 110.76n/a5
Dec ’24CHF 116.60
CHF 132.35
+13.5%
12.0%CHF 156.22CHF 113.18CHF 110.005
Nov ’24CHF 108.60
CHF 132.35
+21.9%
12.0%CHF 156.22CHF 113.18CHF 114.605
Oct ’24CHF 115.80
CHF 125.20
+8.1%
10.1%CHF 142.98CHF 114.01CHF 123.203
Sep ’24CHF 123.80
CHF 128.43
+3.7%
11.8%CHF 152.39CHF 113.21CHF 130.704
Aug ’24CHF 126.20
CHF 128.43
+1.8%
11.8%CHF 152.39CHF 113.21CHF 125.604
Jul ’24CHF 120.60
CHF 113.93
-5.5%
15.1%CHF 142.93CHF 91.61CHF 122.605
Jun ’24CHF 115.00
CHF 103.57
-9.9%
6.6%CHF 111.63CHF 92.70CHF 123.104
May ’24CHF 120.20
CHF 103.57
-13.8%
6.6%CHF 111.63CHF 92.70CHF 111.804
Apr ’24CHF 99.30
CHF 103.57
+4.3%
6.6%CHF 111.63CHF 92.70CHF 121.804
Mar ’24CHF 101.00
CHF 106.79
+5.7%
4.5%CHF 111.99CHF 99.33CHF 127.804
Feb ’24CHF 99.30
CHF 106.39
+7.1%
2.6%CHF 110.50CHF 102.87CHF 130.704
Jan ’24CHF 103.60
CHF 106.02
+2.3%
3.1%CHF 109.36CHF 100.91CHF 126.004
Dec ’23CHF 102.00
CHF 106.02
+3.9%
3.1%CHF 109.36CHF 100.91CHF 116.604

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 06:04
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Medacta Group SA is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Samuel EnglandBerenberg
Christoph GretlerCredit Suisse
David AdlingtonJ.P. Morgan